New Anti-Obesity Drug Retatrutida Achieves Record 30% Weight Loss in Clinical Trials

A new anti-obesity drug, retatrutida, has shown unprecedented results in clinical trials, leading to an average weight loss of 30.3% (38.5 kg) over two years in individuals with morbid obesity, marking a significant breakthrough in GLP-1 related medications.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

el-mundoSpanish99d ago

Un nuevo fármaco antiobesidad rompe récords al lograr una pérdida de peso del 30% a los dos años

Los resultados de retatrutida, la tercera generación de los medicamentos GLP, muestran reducciones medias de 38,5 kg, equivalentes al 30,3% del peso corporal, en personas con obesidad mórbida Leer

Read full article →

PERSPECTA

PERSPECTA

New Anti-Obesity Drug Retatrutida Achieves Record 30% Weight Loss in Clinical Trials

Sources

Un nuevo fármaco antiobesidad rompe récords al lograr una pérdida de peso del 30% a los dos años

Related Stories

Partial Lunar Eclipse Captured by Stargazers Across Multiple Continents

Global Observers Watch Partial Lunar Eclipse Covering Most of Moon

Partial Lunar Eclipse Draws Global Viewers Despite Cloudy European Skies

Rare Partial Lunar Eclipse to Cast Red Glow Across Northern Skies

PERSPECTA